T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
Status:
NOT_YET_RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Bevicizumab in HER2-low breast cancer with brain metastasis.